’Fasten your seatbelts’— BTIG strategists warn of coming turbulence
On Tuesday, JMP Securities analyst David Turkaly confirmed a Market Outperform rating with a $100.00 price target on Haemonetics Corporation (NYSE:HAE) shares. Following the company’s fourth-quarter fiscal year 2025 earnings release, Turkaly highlighted Haemonetics’ consistent performance, noting revenues of approximately $331 million met market expectations and the company achieved a modest earnings beat. According to InvestingPro data, the company maintains healthy profitability with a 57.5% gross margin and is currently trading below its Fair Value, suggesting potential upside opportunity.
Haemonetics concluded its fiscal year with a focus on margin growth and restructuring efforts. These changes followed the conclusion of a supply partnership with CSL (OTC:CSLLY) in 2021, which had been extended through the fiscal year 2025. Additionally, Haemonetics divested its Whole Blood business in December 2024. InvestingPro analysis reveals the company’s strong financial health, with a robust current ratio of 1.62 and sufficient cash flows to cover interest payments.
The analyst expressed optimism regarding Haemonetics’ forward-looking guidance for fiscal year 2026, which surpassed JMP Securities’ projections. The company anticipates increased market share in the Plasma segment and heightened utilization in the Hospital segment in the upcoming quarters.
Turkaly commended Haemonetics on laying a strong foundation for future growth, citing the company’s effective cost-control measures and infrastructure developments. These strategic initiatives are expected to support Haemonetics in reaching its forthcoming financial targets.
In other recent news, Haemonetics Corporation reported its fourth-quarter 2025 earnings, surpassing analysts’ expectations with an adjusted EPS of $1.24, compared to the forecast of $1.22. The company also slightly exceeded revenue projections, reporting $331 million for the quarter. These results were driven by significant growth in the hospital and interventional technologies segments. Additionally, Haemonetics executed a $150 million share buyback program, reflecting its commitment to shareholder value. Analyst discussions during the earnings call included questions about the company’s plasma market share gains and challenges in the vascular closure market. Haemonetics’ CEO, Chris Simon, highlighted strategic execution and value creation, emphasizing the company’s focus on high-growth, high-margin products. Looking ahead, Haemonetics forecasts a decline in fiscal 2026 revenue by 3% to 6% on a reported basis, with organic growth excluding CSL expected between 6% and 9%. The company anticipates an improvement in its adjusted operating margin to 26-27% and projects adjusted EPS between $4.70 and $5.00.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.